VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has named Raju Willener as its new chief financial officer, effective immediately. The appointment brings a veteran of global finance to the helm of the company's financial operations, underscoring VERAXA's commitment to advancing its proprietary BiTAC technology and expanding its oncology pipeline. Willener will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a pivotal role in shaping the company's capital strategy and identifying strategic opportunities.
Willener's career spans more than three decades in international financial leadership, with extensive experience in global capital markets, investment banking, corporate finance, asset management, and strategic leadership. Prior to joining VERAXA, he served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier, he held senior executive and investment positions, overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. This depth of experience is expected to be instrumental as VERAXA navigates the complex landscape of biotech financing and development.
The announcement comes at a critical time for VERAXA, which is leveraging its suite of transformative technologies to develop bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. The company's pipeline is built on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), and its proprietary BiTAC format is a registered trademark of VERAXA Biotech GmbH. With Willener's financial expertise, VERAXA aims to strengthen its position in the competitive oncology space and accelerate the clinical development of its candidates.
According to the company, Willener's role will be central to supporting capital-raising efforts and evaluating strategic partnerships that could enhance the value of its technology platform. His background in managing large investment portfolios and leading corporate development initiatives aligns with VERAXA's goals of maximizing shareholder value and bringing innovative cancer therapies to patients. The company's focus on quality-by-design principles and its rapid advancement of ADC and BiTAC formats into clinical development highlight the urgency of having a seasoned CFO to guide financial strategy.
For investors, the appointment signals confidence in VERAXA's future trajectory. The company's newsroom, available at http://nnw.fm/VRXA, provides the latest updates on corporate developments. As VERAXA continues to progress its pipeline, the addition of a financial leader of Willener's caliber could be a key driver in securing the resources needed to advance its clinical programs and potentially bring new treatment options to patients with cancer.
The move also reflects a broader trend in the biotech industry, where companies are increasingly appointing executives with deep financial and strategic expertise to navigate the complexities of drug development and capital markets. With Willener on board, VERAXA is well-positioned to execute its business plan and pursue growth opportunities in the evolving landscape of antibody-based therapeutics.
